Mitochondrial dysfunction has been reported in both familial and sporadic Parkinson's disease (PD). However, effective therapy targeting this pathway is currently inadequate. Recent studies suggest that manipulating the processes of mitochondrial fission and fusion has considerable potential for treating human diseases. To determine the therapeutic impact of targeting these pathways on PD, we used two complementary mouse models of mitochondrial impairments as seen in PD. We show here that blocking mitochondrial fission is neuroprotective in the PTEN-induced putative kinase-1 deletion (PINK1 À / À ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse models. Specifically, we show that inhibition of the mitochondrial fission GTPase dynamin-related protein-1 (Drp1) using gene-based and small-molecule approaches attenuates neurotoxicity and restores pre-existing striatal dopamine release deficits in these animal models. These results suggest Drp1 inhibition as a potential treatment for PD.
P
arkinson's disease (PD), a neurological disorder characterized by degeneration of the nigrostriatal dopamine (DA) pathway, currently has no established neuroprotective or neurorestorative treatments. The link between mitochondrial dysfunction and PD has been proposed since the discovery of parkinsonism in humans caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-contaminated synthetic meperidine. However, it was the discovery of mutations in PTEN-induced putative kinase-1 (PINK1), as a cause of autosomal recessive PD that established a strong genetic link between PD and mitochondria. Other PD-linked mutations such as a-synuclein, LRRK2, parkin and DJ-1 have also been demonstrated to adversely affect mitochondrial function. These recent genetic studies also have uncovered mitochondrial dynamics (fission/ fusion/movement) as a potential therapeutic target for PD [1] [2] [3] [4] [5] .
Mitochondria are dynamic and they undergo frequent changes in shape, size, number and location. These alterations can be affected by mitochondrial morphology, which in turn, is controlled mainly by the processes of fission and fusion. In mammals, the outer mitochondrial proteins mitofusins (Mfn1 and Mfn2) and the inner mitochondrial protein optic atrophy 1 (OPA1) are responsible for mitochondrial fusion. Fission on the other hand requires the recruitment of dynamin-related protein 1 (Drp1) from the cytosol to the outer mitochondrial membrane by Fission-1 (Fis1) and mitochondrial fission factor (Mff). This process produces multiple smaller mitochondria, which are more motile within the cell. Fission is also important for mitochondrial quality 2, 6 . In contrast to fission, fusion results in larger mitochondria, which could offer a larger ATP supply and also facilitate inter-mitochondrial exchange of substrates and mitochondrial DNA (mtDNA) leading to functional complementation between defective and functional mitochondria 2, 7 . The dynamic relationship between fission and fusion also plays a role in regulating cell death through cytochrome c release. Consequently, a balance of fusion and fission is crucial not only to mitochondrial morphology, but also to cell viability and synaptic function.
Synaptic dysfunction has gained attention in recent years as an early pathology that arises before neurodegeneration in different neurological disorders, including PD 8, 9 . PD genetic models demonstrate that parkin, DJ-1, PINK1, a-synuclein and LRRK2 play a role in striatal presynaptic DA release. However, the mechanisms by which presynaptic dysfunction is caused by these mutations remain largely unknown. Relevant to the present study, mitochondria play a crucial role in presynaptic function 4, [10] [11] [12] , consistent with high energy demand by synaptic terminals to maintain synaptic membrane potential, restore ionic gradients following synaptic transmission and reload synaptic vesicles with neurotransmitters. In addition, presynaptic mitochondria play a major role in sequestration of cytosolic Ca 2 þ during normal neurotransmission 10, 11 . Further supporting the role of mitochondria in presynaptic release, pharmacological and genetic blockade of mitochondrial function have been demonstrated to depress synaptic transmission 13 . Taken together, restoring mitochondrial function may therefore attenuate synaptic failure and neurodegeneration in PD.
Previous studies including our own reported that blocking Drp1 function was sufficient to attenuate mitochondrial dysfunction and neurotoxicity in PD cell culture models [14] [15] [16] [17] [18] . However, to date, the in vivo significance of blocking this mitochondrial fission protein in animal models of nigrostriatal dysfunction has remained undetermined. In this study, we utilized complementary mouse models with mitochondrial impairments in the nigrostriatal system: Pink1-knockout (Pink1 À / À ) mice represent a human disease relevant target with impairments in mitochondrial complex I function and evoked striatal DA release [19] [20] [21] [22] . The neurotoxin MPTP-treated mice provide a model of complex I inhibition with nigrostriatal neurotoxicity 23 . Because both mitochondrial fission and fusion are important for cellular homeostasis, we assessed both manipulation strategies. We report here that blocking mitochondrial fission is beneficial in these animal models.
Results Adeno-associated virus (AAV2)-mediated expression of Drp1-K38A and Fis1 in DA neurons. We previously demonstrated that the Drp1-dominant negative Drp1-K38A mutant was protective in stable dopaminergic neuronal cell model of PD 14 . This genetic approach has also been extensively used to block Drp1 function in various in vitro disease models 15, 16, 24 . In the present study, we performed supranigral injections of recombinant adeno-associated virus (rAAV2) to deliver Drp1-K38A to block mitochondrial fission, Fis1 to promote fission or enhanced green fluorescent protein (eGFP) as a control (Fig. 1a) . Using convection-enhanced gene delivery technique, robust protein expression was detectable 8 weeks later throughout the substantia nigra pars compacta (SNc) and striatum from rostral to caudal regions ( Fig. 1b-o) . Transduction efficiency in nigral DA neurons was calculated as we previously described by quantifying tyrosine hydroxylase (TH)-positive neurons transduced with eGFP 25 (Fig. 1b) . Both PINK1 þ / þ and PINK1 À / À mice had comparable transduction rates (71.3% ±0.05 versus 74.0% ± 0.05, respectively. Data represent mean ± s.e.m., n ¼ 3 mice per group).
Drp1-K38A and Fis1 alter mitochondrial morphology in vivo. After 8 weeks to allow sufficient time for protein expression in the nigral DA neurons, we determined the effects of fission/fusion proteins on mitochondrial morphology. Given the heterogeneous mitochondrial morphology observed between cell types (Fig. 2a) , we performed immuno-electron microscopy to specifically carry out analyses in striatal DA terminals (Fig. 2b,c, Supplementary  Fig. 1 ), a site where mitochondria control presynaptic release of DA in the nigrostriatal pathway. Quantitative morphological analysis confirmed that as compared with the eGFP group, there was a larger proportion of elongated mitochondria in mice expressing Drp1-K38A and an increased fraction of smaller mitochondria in the Fis1 group (Fig. 2d) , consistent with the role of blocking and promoting fission of these proteins, respectively. Two-way analysis of variance analyses indicate these alterations were Pink1-independent as no difference between genotypes was detectable in the absence or presence of these constructs, suggesting mitochondrial morphology in DA terminals of mice with germline deletion of Pink1 is not altered, and furthermore, mitochondrial dysfunction in Pink1 À / À mice 20, 21 is not necessarily linked to mitochondrial fragmentation as seen in cell culture models with transient or acute loss of PINK1 function [14] [15] [16] 26 .
Drp1 inhibition restores DA release in Pink1 À / À mice. Mitochondria from Pink1 À / À mice exhibit respiratory dysfunction 20, 21 and evoked DA release is impaired in acute striatal slices of these animals 22 . These observations are consistent with the crucial role of mitochondria in presynaptic release 4, 10, 11 . We asked whether this deficit in DA release also occurred in vivo, and if so, whether blocking or promoting fission would rectify this defect. To this end, we used in vivo microdialysis to assess depolarization-induced DA overflow in the striatum of freely moving Pink1 À / À and Pink1 þ / þ littermates. Pink1 À / À mice exhibited significantly reduced DA overflow compared with Pink1 þ / þ controls ( Fig. 3a-d , Table 1 ). Simultaneous quantification of serotonin (Fig. 3e ) in these dialysates suggests this deficit was specific to DA. Of note, impaired DA overflow in Pink1 À / À mice was not a result of nigrostriatal damage (Fig. 3f) or increased dopamine transporter (DAT) activity 22 . Our observation here provides in vivo evidence of impaired exocytotic DA release in Pink1 À / À mice. However, 8 weeks after receiving Drp1-K38A (Fig. 3a,b , Table 1 ), but not Fis1 (Fig. 3c,d Table 1 ), a restoration of evoked DA overflow was achieved in Pink1 À / À mice, suggesting blocking, but not promoting fission, is beneficial. Furthermore, in Pink1 þ / þ littermates, Drp1-K38A had no detectable effect, whereas Fis1 significantly reduced DA release. Because no changes in the number of nigral DA neurons, striatal DA terminals and total DA content occurred (Fig. 3f) , the alterations in DA release were related to function, not structure of the nigrostriatal pathway. Together, these results indicate that blocking mitochondrial fission is capable of ameliorating pre-existing DA synaptic dysfunction in Pink1 À / À mice. In addition, in contrast to Fis1, Drp1-K38A does not appear to negatively impact DA release in Pink1 þ / þ mice.
As a complementary approach to Drp1-K38A, we turned to the small molecule termed Mitochondrial Division Inhibitor-1 (Mdivi-1) 27 . This Drp1 inhibitor has been demonstrated to be protective by blocking mitochondrial fission in cell culture 28, 29 and rat neuropathic pain 33 . We first assessed whether this molecule crossed the blood-brain barrier because this property had not been demonstrated in previous studies. Using a newly developed high-performance liquid chromatography (HPLC) method, peak plasma levels of mdivi-1 were seen 1 h after intraperitoneal (i.p.) injection, followed by peak brain levels 2 h later, confirming this lipophilic molecule is permeable to the blood-brain barrier (Fig. 4a) . Based on the estimated half-life of mdivi-1 in the brain (B8.9 h), we chose a twice daily dosing regimen in the subsequent studies. Similar to Drp1-K38A, more mitochondrial elongation was detectable in mice treated with mdivi-1 twice daily for 3 days compared with the group that received vehicle control (Fig. 4b,c) . Furthermore, this small molecule also restored evoked DA overflow in Pink1 À / À mice (Fig. 4d , Table 2 ). As subsequently illustrated in Fig. 7a ,b, mdivi-1 did not affect DA outflow in wild-type mice.
To eliminate the possibility that this enhanced DA overflow in Pink1 À / À mice was not due to mdivi-1 interfering with DA reuptake, we utilized stable cells overexpressing DAT in the presence of its substrates 1-methyl-4-phenylpyridinium (MPP þ ; Fig. 4e ). Mdivi-1 did not have an effect on DAT function up to 10 mM. In contrast, 1 mM of GBR 12909 (a DAT inhibitor) blocked more than 90% of DAT transport activity. Collectively, these results indicate mdivi-1 is capable of ameliorating the pre-existing DA release deficits in Pink1 À / À mice.
Drp1 inhibition attenuates dopaminergic neurotoxicity. To determine the impact of Drp1 inhibition against neurotoxicity in the nigrostriatal pathway, B10-week-old CB7Bl/6 mice received gene delivery as described above for 8 weeks before MPTP injections. Drp1-K38A significantly attenuated damage induced by MPTP (Fig. 5a-d) . To further support that Drp1 inhibition protected against cell loss, rather than increasing the expression of the phenotypic marker tyrosine hydroxylse (TH), we also performed stereological counting of Nissl-positive neurons in the SNc (Fig. 5b) . These quantitative data indicate that, first, at this time point (7 days after the last MPTP injection), there was a significant loss of nigral neurons, not a downregulation of TH phenotype 34 , consistent with our previous validation 35 . Second, Drp1-K38A prevented cell loss, and thus did not merely promote re-expression of the TH marker. Consistent with the effect of this Drp1 dominant negative, twice daily injections of mdivi-1 to adult C57Bl mice during MPTP treatment also prevented neurotoxicity of DA neurons, striatal terminals and total striatal DA content (Fig. 5e-h ). Of note, Mdivi-1 did not interfere with the brain levels of 1-methyl-4-phenylpyridium (MPP þ ) after Drp1 inhibition improves DA release in MPTP pre-treated mice. Considering the substantial amount of nigrostriatal degeneration already present at the time of diagnosis in humans with PD, we aimed to more closely model this scenario and assessed the functional impact of blocking Drp1. To this end, mice received MPTP as described above, however, we delayed gene delivery until 7 days after the last injection to allow the lesion to form and stabilize before intervention. We hypothesized that among the remaining nigrostriatal neurons, there would exist a sizable dysfunctional fraction that could be ameliorated by promoting mitochondrial fusion-a process that could restore mitochondrial function through functional complementation between defective and functional mitochondria 2, 7 . In MPTP pre-lesioned mice, both Drp1-K38A (Fig. 6a,b , Table 3a ) 
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(e-h) C57Bl/6 mice receiving MPTP or saline were injected i.p. with Mdivi-1 (20 mg kg À 1 ) or vehicle twice daily until day the mice were killed. Seven days after the last MPTP injection, neuropathology was assessed. n ¼ 4-7 per group, analysed by one-way ANOVA followed by Newman-Keuls post-hoc test. *Po0.05 compared with animal receiving MPTP without mdivi-1; # Po0.05 compared with animals receiving saline. 
Discussion
Targeting mitochondrial dynamics as a potential therapeutic for neurodegenerative diseases has been highlighted in recent years [1] [2] [3] [4] [5] . Overall, it has been documented that either too much fission or fusion is not conducive to optimal mitochondrial function. Hence, such imbalances could negatively impact synaptic function and neuronal viability. In cell culture models, in addition to PD-linked mutations, neurotoxic molecules such as rotenone 36 , MPP þ (ref. 17) , methamphetamine 37 and 6-hydroxydopamine 18 , which are capable of damaging the nigrostriatal pathway, cause mitochondrial fission and neurotoxicity that can be attenuated by blocking mitochondrial fission or promoting fusion. Thus, perturbed mitochondrial dynamics may represent a shared mechanism that underlies both genetic and toxin-induced related PD. The present study utilizes both genetic and neurotoxic models of nigrostriatal dysfunction to determine the in vivo significance of targeting mitochondrial fission/fusion in PD.
Pink1 À / À mice were used to represent a human genetic model with impairments in mitochondrial complex I function and evoked striatal DA release [19] [20] [21] [22] . The recognition that synaptic dysfunction is an early and likely pathogenic factor in neurodegenerative disorders 8, 9 and the much shorter lifespan in mice compared with humans have led to the view that such genetically engineered mice may model the early pre-clinical stages of PD 38 . In the present study, we observed that blocking mitochondrial fission via Drp1 inhibition rescues DA release deficits in Pink1 À / À mice. Although the role of PINK1 on mitochondrial fission/fusion remains a topic of debate, primarily due to conflicting observations between the published Drosophila and mammalian cell culture studies, insights into these discrepancies have recently been extensively discussed 3, 39 . Briefly, loss of PINK1 function has been demonstrated to tip the balance of fission/fusion towards an overall pathogenic mitochondrial fission in mammalian immortalized cell models [14] [15] [16] 26 . In Drosophila models, however, Pink1 has the opposite effect [40] [41] [42] . Potential explanations for this discrepancy include the time when morphological analysis is performed after a loss of PINK1 function occurs and different compensatory mechanisms between models. Because of space constraints, further detailed discussion on this topic can be found in these reviews 3, 39 . Although additional studies are required to address this issue, it is crucial to move forward to mammalian animal models to address whether blocking or promoting mitochondrial fission is beneficial to a compromised nigrostriatal dopaminergic system. Our study is designed to shed light on this critical question. The lack of detectable changes in mitochondrial morphology in mice with germline deletion of Pink1 in the current study is consistent with the argument that the effect of PINK1 on mitochondrial morphology is transient and acute 3, 39 . Studies using primary neurons or fibroblasts from Pink1 À / À mice also do not display mitochondrial fragmentation 20, 43, 44 . Despite the inconsistent observations of changes in mitochondrial morphology, a loss of PINK1 function is consistently reported to result in mitochondrial dysfunction across various models, suggesting mitochondrial morphology is not necessarily linked to mitochondrial dysfunction induced by a loss of PINK1 function. In the absence of mitochondrial fragmentation in Pink1 À / À mice, the intriguing question is why does promoting mitochondrial fusion via blocking Drp1 function restored DA release in these animals? It has been established that within a single cell, wild-type mtDNA and mutant variants can co-exist (heteroplasmy) and when the damaged load exceeds a threshold of 460%, mitochondrial dysfunction occurs 45, 46 . By promoting exchanges of mitochondrial contents and DNA between functional and defective mitochondria within heteroplasmic cells, mitochondrial fusion can dilute defective mitochondria and attenuate their negative impact through functional complementation 2, 7 . Loss of PINK1 function has been reported to result in mtDNA mutations and defects in the electron transport chain in humans and experimental models 47, 48 . It is possible that functional complementation contributes to the beneficial effects observed in this model.
Owing to the lack of neurodegeneration in Pink1 À / À mice, we turned to the well-established MPTP mouse model to address the following questions: first, could Drp1 inhibition prevent neurotoxicity in the nigrostriatal pathway? Second, under the scenario of pre-established loss of DA neurons as seen in PD, could Drp1 inhibition enhance DA release? As demonstrated, both AAVmediated and small-molecule approaches conferred such beneficial effects in the MPTP model. These in vivo observations are also consistent with a previous in vitro study in which either silencing Drp1 or expressing Drp1-K38A attenuates mitochondrial dysfunction induced by MPP þ (ref. 17) . A recent study using a complementary approach of overexpressing OPA1 also reports protection in the MPTP mouse model 49 . However, because we evaluated the protective effects of Drp1 inhibition in mice 7 days after the last MPTP injection, we cannot entirely rule out the possibility that such treatment delayed rather than prevented neurotoxicity. Future studies are needed to assess whether blocking mitochondrial fission or promoting fusion also confers neuroprotection in a longer time point post MPTP injection.
Drp1 plays an important role in the induction of cellular apoptosis pathways by regulating cytochrome c release. Indeed, Drp1 and the pro-apoptotic protein Bax co-localize at cleavage sites during fission 50 . Inhibition of Drp1 via pharmacological (mdivi-1) 27 or genetic 51 strategies exerts anti-apoptotic effects. Relevant to our data, MPTP has been demonstrated to induce cell death in vivo partly through Bax-dependent cytochrome c release 49 . Hence, because mitochondrial fission, Drp1 activity, and apoptosis are often not mutually exclusive events, it is possible that the neuroprotective effects of blocking Drp1 function in our MPTP studies are due to blocking cytochrome c release. Furthermore, because damage or mutations in mtDNA in nigral DA neurons have been detected after MPTP treatment 52, 53 , blocking Drp1 may also confer protective effects through functional complementation in our studies.
Drastic alterations in either fission or fusion in a 'normal' neuron is not conducive to neuronal function and viability in animal models. For example, Drp1 knockout causes embryonic lethality and degeneration of Purkinje neurons in mice [54] [55] [56] . Similarly, deletion of the mitochondrial fusion gene OPA1 is also embryonically lethal 57 . Although heterozygous OPA1 mutant mice are viable, they exhibit synaptic loss 58 , a neuropathology that precedes neurodegeneration. Together, these animal models indicate that germline deletion of mitochondrial fission/fusion genes is detrimental. In contrast to the knockout mouse models above, we did not completely delete Drp1 in our study. With our Drp1-blocking strategies, it is most likely that mitochondrial fission is not entirely blocked and thus the residual effects are sufficient for the maintenance of normal physiological functions. This is a likely scenario given that only B3% of total Drp1 is required by mitochondria for the maintenance of normal physiological functions 59 . Furthermore, we target Drp1 under pathological setting such as MPTP toxicity, which excessively enhances Drp1 function 17 . Mice systemically injected with mdivi-1 were also viable and no abnormal phenotypes were detectable. At cellular and functional levels as shown in our study (Figs 4,5,7) , we did not detect neurotoxicity of this molecule in the brain. The effects of this molecule in the peripheral system have also recently been assessed. Using the same regimen, Mdivi-1 did not affect blood pressure, oxygen saturation, pH and blood cell counts 29 .
Mitochondrial fission is critical to mitophagy and mitochondrial motility. Cell culture studies show that blocking fission or promoting fusion impairs these processes 6 . Although this in vitro study cautions the potential negative impacts of altering fission/ fusion, our results indicate blocking Drp1 function using our strategies does not affect synaptic release or cell viability in adult Pink1 þ / þ and regular C57BL/6 mice. Together, these studies suggest a potential difference between cell culture and animal studies. As discussed above, it is possible that mitochondrial fission is not entirely blocked by Drp1-K38A or mdivi-1 and thus the residual effects are sufficient for the maintenance of normal physiological functions. Furthermore, other studies have shown that under stressful (nutrient deprivation) or certain pathological conditions (mutant a-synuclein and huntingtin), blocking mitochondrial fission and promoting fusion protect against mitophagy [60] [61] [62] and enhance mitochondrial motility 24 . The crucial role of mitochondrial fusion in the nigrostriatal system has also been recently demonstrated in a mouse model with conditional deletion of Mfn2 in DA neurons 63 . The loss of this mitochondrial fusion gene results in progressive retrograde neurodegeneration and L-3,4-dihydroxyphenylalanine responsive locomotor deficits. Simultaneous deletion of Mfn2 in DA neurons in the ventral tegmental area further reveals that nigral DA neurons are most vulnerable to reduced mitochondrial fusion.
Mitophagy mediated by concerted efforts of PINK1 and parkin has also been a topic of interest in recent years. Parkin is recruited by PINK1 to mitochondria with depolarized membrane potential to initiate mitophagy 64 . Most of the studies that characterize the effects of overexpressing PINK1 and Parkin on mitophagy have been performed in immortalized cells such as HeLa, MEF and SH-SY5Y cells using strong protonophores such as CCCP to collapse membrane potential. However, to date, many questions remain to be addressed. For example, what is the physiological relevance of this pathway in the mammalian brain or in the presence of endogenous levels of PINK1/Parkin? At endogenous levels, Parkin fails to mediate mitophagy in human primary fibroblasts and induced pluripotent stem cell-derived neurons 65 . Mice with mitochondrial transcription factor A deletion in dopaminergic neurons exhibit mitochondrial fragmentation, mtDNA depletion and neurodegeneration 66 ; however, mitophagy was not detectable in the brain of these animals-even when Parkin was overexpressed using AAV 66 . Furthermore, when these mutant mice were crossed with Parkinknockout mice, they did not exhibit more accumulation of damaged mitochondria and neurodegeneration 66 . Collectively, the in vivo significance of mitochondrial fission and PINK1 in mitophagy remains to be established.
In summary, the present study was designed to concisely address one central question: What is the functional impact of blocking or promoting fission on the nigrostriatal pathway in animal models with mitochondrial dysfunction? Our results demonstrate that blocking Drp1 function is protective against active neurotoxicity and is capable of restoring DA release under conditions of pre-existing pathology. In the latter scenario, although blocking Drp1 does not promote regeneration of DA neurons in the MPTP model with pre-established lesions (at least not within this short period of time), the combination of preventing cell loss and functional recovery of DA release in the remaining neurons is likely to be beneficial. The current cornerstone of PD treatment still remains DA replacement therapy. Given current interest on whether or in which direction promoting fusion or fission would affect synaptic release and neurodegeneration in vivo, we believe our results shed light on this critical issue and encourage additional future in-depth studies in this field.
Methods
Plasmids. Drp1-K38A and Fis1 in pcDNA3 plasmids 14 were kindly provided by Dr Yisang Yoon (Georgia Regents University). To monitor the expression of these proteins after rAAV2 injections, we tagged Drp1-K38A with eGFP and hFis1 with myc, at the C-terminus using standard molecular biology techniques. Based on similar procedures as described by the Bowers Laboratory 67 , these genes were subcloned into the pBSFBRmcs shuttle vector using the following sites: AgeIBamHI for Drp1-K38A-eGFP and BamHI-EcoRI for Fis1-myc. The expression cassettes of these genes containing the cytomegalovirus promoter (CMV) were excised using NotI and then ligated (also using NotI) into a modified pFBGR plasmid backbone devoid of the CMV-eGFP expression cassette. The pFBGR plasmid harbours a CMV-driven eGFP gene flanked by inverted terminal repeats. This original pFBGR plasmid was used as an empty vector control for rAAV2 transduction. All pFB-related plasmids were then transiently transfected into baby hamster kidney cells and transgene expression was confirmed using immunocytochemistry before viral packaging.
Mice. The animal procedures described in this study were approved by the University Committee on Animal Resources under the protocol # 2006-102R. All mice were housed in the animal facilities of the University of Rochester School of Medicine. Animals had free access to water and food. Veterinary care includes a full programme for prevention of disease, daily observation and surveillance for animal health, appropriate methods of disease control, diagnosis and treatment, appropriate methods of handling, restraint, anaesthesia, analgesia and euthanasia as well as monitoring of surgical programmes and post-surgical care. The generation of Pink1 À / À mice with a targeted germ-line deletion of exons 4-7 and a portion of exon 8 has been described 68 and these animals have been backcrossed to C57Bl/6 background over nine to ten generations. Heterozygous breeders (Pink1 þ / À ) were kept in the pathogen-free barrier area of the Micro-Isolator Facility. All Pink1 À / À and their Pink1 þ / þ male littermates used in this study were approximately 11-to 13-month old.
rAAV packaging. These procedures were performed according to the previous publications from the Bowers Laboratory 67 . Briefly, rAAV2 was produced by co-infecting cultures of SF9 cells at log phase (2 Â 10 6 cells per ml) with passage 2 baculovirus of pFBDAAV (serotype viral proteins), and pFBDLSR (Rep 52 and Rep 72) and pFB-Drp1-K38A-eGFP, pFB-Fis1-myc or pFB-eGFP at a multiplicity of infection (MOI) ¼ 5 each. Cultures were incubated for 72 h at 28°C and harvested by centrifugation. Pelleted cells were resuspended in PBS with MgCl 2 , serially frozen at À 70°C and thawed at 37°C three times. The lysates were centrifuged and optical grade CsCl 2 (Shelton Scientific) was added to supernatant; final concentration was confirmed by refractive index. rAAV particles were banded on a CsCl 2 gradient by ultracentrifugation. Fractions with a refractive index of 1.374-1.370, corresponding to the position of viable viral particles, were collected and subsequently dialysed against PBS. AAV particles were titred, relative to rAAV-eGFP titres that were packaged in parallel, by transduction assay followed by flow cytometry and quantitative real-time PCR.
Stereotactic injections of rAAV2. C57Bl/6 male mice (B10-week old) or Pink1 À / À mice and Pink1 þ / þ littermates (approximately 1-year old) received either bilateral or unilateral supranigral stereotactic injections of rAAV2 capsids. Under Avertin anaesthesia (300 mg kg À 1 ), mice were positioned in a stereotactic apparatus and an incision was made to expose bregma on the skull. Burr holes were drilled over the injection coordinates (relative to bregma: À 3.1 mm caudal, ± 1.3 mm lateral, À 4.2 mm ventral). The injection setup consisted of a framemounted micromanipulator, holding an UltraMicro pump (WPI Instruments) with a Hamilton syringe and a 33-GA needle (Hamilton). The needle was lowered into the parenchyma at a rate of 0.8 mm min À 1 , and then held in place for 2 min before injection. rAAV2 vectors (5 Â 10 9 transducing units) were delivered either unilateral or bilateral to the substantia nigra in a 5-ml volume using convection enhanced delivery (a method enhancing tissue volume receiving virus) by using increasing step-wise injection rates of 100 nl min À 1 for 6 min, 200 nl min À 1 for 10 min and 400 nl min À 1 for 6 min. After injection, the needle was allowed to rest in place for 2 min, then withdrawn at a rate of 0.4 mm min À 1 . Incisions were sutured with 4-0 Vicryl (Ethicon, Inc.), triple antibiotic and lidocaine topical ointments were applied, and mice placed in a recovery chamber at 37°C overnight.
MPTP and rAAV treatments. For all studies, approximately 10-to 12-week-old male C57Bl/6 mice were randomly assigned to receive i.p. injections of MPTP (20 mg kg À 1 , Sigma) or saline once daily for 5 days. For neuroprotection studies, MPTP injections began 8 weeks after rAAV2 delivery and mice were killed 7 days after last MPTP dose. For neuro-rescue studies, rAAV2 was delivered 7 d after the last MPTP injection and mice were killed 8 weeks later. Mice were decapitated and freshly removed brains were bisected coronally B1-2 mm caudal to optic chiasm. The caudal portion (midbrain) was immediately placed in 4% paraformaldehyde (PFA) for 24 h. The rostral portion (striata) was divided mid-sagittally. Randomly, one half was placed in 4% PFA for 24 h, whereas the other was processed for HPLC analysis. After 24 h in 4% PFA, tissue was cryoprotected in 15%, then 30% sucrose phosphate buffer, then frozen at À 80°C for immunohistochemical studies.
Mdivi-1 preparation. Mdivi-1 (3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone) was purchased from Enzo Life Sciences International, Inc. and dissolved in dimethylsulphoxide (DMSO; 100 mg ml À 1 ) as a stock solution. For injections, mdivi-1 was diluted in sterile saline (1% DMSO). Owing to the poor aqueous solubility of mdivi-1, each dose was gently sonicated (Model S3000 Sonicator with tapered microtip; Misonix, Inc.) at a power level 0.5-1 for 30 s producing a homogenous suspension and injected i.p. immediately. For cell culture experiments, mdivi-1 stock solution was diluted in culture medium to varying working concentrations.
Serum and brain levels of mdivi-1. C57Bl/6 mice were injected i.p. with mdivi-1 (20 mg kg À 1 in sterile saline containing 1% DMSO) and killed 0.5, 1, 3, 6, 12 and 24 h later. Mice were decapitated and blood was collected in heparinized tubes and centrifuged at 2,000 g for 10 min at 4°C. Collected serum (100 ml) was gently vortex with acetonitrile (200 ml) for B10 s and centrifuged at 14,000 g for 15 min. Supernatant was collected for HPLC analysis. Fresh brain samples were homogenized in 5 volumes (wt/vol) saline via sonication for 5-10 s. For every 100 ml homogenate, 200 ml acetonitrile was added and sonicated again to extract mdivi-1. After centrifugation at 14,000g for 15 min at 4°C, supernatant was collected for HPLC analysis as described below. Half-life of mdivi-1 was calculated using the following equations: (K elim ¼ [ln(C peak )-ln(C trough )/T interval and T 1/2 ¼ 0.693/k elim ).
MPTP and mdivi-1 treatments. For all studies, 10-to 12-week-old male C57BL/6 mice were randomly assigned to receive i.p. injections of either MPTP (20 mg kg À 1 , Sigma) or saline once daily for 5 days. For the neuroprotection ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6244 studies, mice received twice daily i.p. injections (20 mg kg À 1 ) with mdivi-1 beginning on the day of the first MPTP injection and continued until mice were killed 7 days after last MPTP injection. For the neurorestorative studies, mice received twice daily i.p. injections (20 mg kg À 1 ) with mdivi-1 beginning 7 days after the last MPTP injection and continued for a total of 3 days. To maximize the data yielded from each animal, mice were killed by decapitation and the freshly removed brains were divided into three pieces for separate measures of nigrostriatal damage. Upon removal, brains were first divided into rostral and caudal sections via a coronal cut approximately 1-2 mm caudal to the optic chiasm. The caudal portion containing the midbrain was immediately placed in 4% PFA for 24 h. The rostral portion containing the striatum was then divided mid-sagittally into right and left halves. Randomly, one half was placed in 4% PFA for 24 h, whereas the other was processed for HPLC analysis of total striatal DA. After 24 h in 4% PFA, tissue was cryoprotected in successive 15 and 30% sucrose phosphate buffer for 2 days then frozen at À 80°C for immunohistochemical studies.
Immunohistochemistry and co-localization. Coronal brain sections (30 mm) from mice receiving rAAV2-eGFP and Drp1-K38A-eGFP were incubated in M.O.M mouse IgG blocking reagent (Vector Laboratories) overnight before incubation with polyclonal anti-GFP (1:500, Invitrogen) and monoclonal anti-TH (1:500; Sigma). For Fis1-myc, monoclonal anti-myc (1:2,000, 9B11 clone, Cell Signaling) and polyclonal anti-TH (1:500, Calbiochem) were used. Corresponding secondary antibodies Alexa Fluor 488 and 594 (Invitrogen) were used. Nuclei were visualized with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (1:1,000, Invitrogen). Images were scanned at 0.5 mm intervals throughout the whole section and analysed using confocal microscopy (FV1000; Olympus).
Quantification of DA nigral neurons and striatal terminals. These analyses were performed as described 23 . Briefly, animals were anaesthetized with pentobarbital and intracardially perfused with cold 4% (w/v) PFA in 0.1 M PBS (pH 7.4). Their brains were removed, postfixed in the same fixative overnight at 4°C, cryoprotected in successive 15 and 30% sucrose phosphate buffer for 2 days at 4°C. The brains were subsequently frozen in dry ice-chilled isopentane (approximately À 50°C). Serial coronal sections (30 mm) spanning the entire midbrain and striatum were collected free-floating in PBS. Every fourth sections (for mibrain) and every eighth sections (for striatum) spanning from the caudal to rostral boundaries of these brain regions were incubated with a polyclonal anti-TH (Calbiochem) for 48 h at 4°C. Biotinylated secondary antibodies followed by avidin-biotin complex were used. Immunoreactivity was visualized by incubation in 3,3 0 -diaminobenzidine/glucose/ glucose oxidase. Total numbers of TH-positive neurons in SNc were counted stereologically using the optical fractionator method. Striatal optical density of TH-positive fibres was quantified using the Scion Image programme.
Measurements of striatal MPP þ levels. To assess whether mdivi-1 treatment interferes with the conversion of MPTP into MPP þ , 10-to 12-week-old male C57BL/6 mice received a single i.p. injection of mdivi-1 (20 mg kg À 1 ) or vehicle followed immediately by a single i.p. injection of MPTP (25 mg kg À 1 ). All mice were killed 90 min after the injections. Striatal tissue levels of MPP þ were measured using HPLC (CoulArray 5600A, 12-channel, ESA Inc.). Samples (20 ml) were injected manually into a Rheodyne sample injector (with a fixed loop of 20 ml) and eluted on a narrowbore column (ID: 2.1 mm, Altima HP C18 (Alltech Associates, Inc.) using mobile phases consisting of 80.5% 50 mM KH 2 PO 4 and 9.5% acetonitrile, pH 3.2. The flow rate was set at 0.2 ml min À 1 for all measurements.
In vivo microdialysis. Stereotactic implantation of guide cannula was performed as described 69 using the following striatal coordinates, relative to bregma: anteriorposterior þ 0.5 mm, lateral À 2.0 mm, dorsal-ventral À 1.5 mm (from surface of brain). The following day, a microdialysis probe (2-mm membrane, Bioanalytical Systems, Inc.) was inserted into the guide cannula and connected to a low torquedual channel swivel (Instech Laboratories, Inc.), which was connected to a syringe pump perfusing with artificial cerebrospinal fluid (aCSF) at 2 ml min À 1 . After a 2-h equilibration period, dialysates were collected every 15 min for all DA release studies. Two baseline fractions were collected, after which the perfusate was switched to aCSF containing 100 mM KCl (with equimolar reduction in NaCl to maintain osmolality) for 15 min to deliver a total 240 nmol KCl, followed by a return to normal aCSF for 45 min. Afterwards, proper probe placement was verified in each animal. Serotonin and DA were measured in each sample simultaneously. Quantification of these neurotransmitters and amount of KCl delivered to striatum were calculated as described 69 . Briefly, taking into considerations of probe efficiency (B8%), flow rate (2 ml min À 1 ) and duration of sample collection (15 min), values were extrapolated from the standard curves of individual compounds.
HPLC measurements of brain DA and mdivi-1. A 12-channel CoulArray (ESA Inc.) equipped with a highly sensitive amperometric microbore cell (model 5041, ESA Inc.) was used to analyse the content of DA and its metabolites with the cell potential set at þ 220 mV as described 70 . For mdivi-1 pharmacokinetic studies, 20 ml samples were injected manually and separated on a narrowbore column (ID: 2.1 mm, Altima HP C18, Alltech Associates, Inc.) using a mobile phase consisting of 35 mM KH 2 PO 4 and 45% acetonitrile, pH 3.5, and detected at 298 nm using a UV detector (model no. 526, ESA Inc.). The flow rate was set at 0.2 ml min À 1 for catecholamines and 0.4 ml min À 1 for mdivi-1 by using a solvent delivery pump (Model 585, ESA Inc.). Data were collected and processed using the CoulArray data analysis programme.
Transport studies. EM4 cells, human embryonic kidney (HEK 293) cells stably transfected with macrophage scavenger to increase their adherence to tissue culture plastic 70 , overexpressing mouse 70 DAT or empty vector control were grown in 24-well plates. These cells were washed twice and then preincubated for 20 min at 37°C in Krebs Ringer Hepes buffer (125 mM NaCl, 25 mM HEPES, 5.6 mM glucose, 4.8 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , pH 7.4) (ref. 70) , in the absence or presence of mdivi-1 (1 or 10 mM) or GBR12909 (1 mM). This buffer was then replaced with Krebs Ringer Hepes plus or minus MPP þ (200 mM), in the absence or presence of mdivi-1 (1 or 10 mM) or GBR12909 (1 mM, a DAT inhibitor) for 30 min. To stop the reaction, cells were rinsed with ice-cold buffer and then immediately removed in 5% trichloroacetic acid, sonicated and centrifuged at 15,000 g at 4°C for a minute. Supernatant was collected for MPP þ quantification using HPLC as described above. Cell pellet was measured for protein concentration using the BCA assay.
Immuno-electron microscopy. Mice were transcardially perfused with 1% glutaraldehyde/4% PFA in 0.1 M sodium cacodylate buffer, pH 7.4. Perfused brains were blocked in the coronal plane and 3 mm slices of striatum (approximately þ 0.7 to 0.4 mm Bregma) were removed, postfixed and then cryoprotected gradually up to 30% sucrose. Tissue was then cut into 50-mm thick coronal sections using a cryostat. Cryostat sections were treated with 1% sodium borohydride in 0.1 M Tris-buffered saline (TBS) for 30 min, washed thoroughly, then blocked in 5% Normal goat serum, 1% BSA, 0.1% cold water fish gelatin, 1% glycine and 1% lysine in 0.1 M tris-buffered saline for 1 h at room temperature. Tissue was then incubated with polyclonal anti-TH (1:100, Calbiochem) for three nights at 4°C, followed by biotinylated goat anti-rabbit (1:200, Vector Labs) for two nights. Sections were then incubated in ExtrAvidin (1:150, Sigma) for one night at 4°C before being reacted with 3,3 0 -diaminobenzidine, silver enhanced, gold-toned and osmicated (1% OsO 4 ). Dehydrated sections were embedded in EPON/Araldite epoxy overnight, sectioned (80 nm), stained with uranyl acetate and lead citrate and examined using a Hitachi 7650 electron microscope with an attached Gatan 11 megapixel digital camera system. A blinded experimenter obtained images at 20,000 Â of TH-positive terminals, of which a second blinded experimenter quantified the morphology of 50 mitochondria per mouse using ImageJ v1.42 (NIH).
Statistics. All values are expressed as mean ± s.e.m. Differences between means were analysed using a two-tailed t-test, one-way or two-way analysis of variance followed by Newman-Keuls post-hoc testing for pairwise comparison using SigmaStat v3.5. For in vivo microdialysis data, areas under the curve were generated using GraphPad Prism v5.01 as previously described 69, 70 . The null hypothesis was rejected when P-value was o0.05.
